Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis

Journal of Chemotherapy

Volumn 18, Issue 6, 2006, Pages 617-623

  Kubendiran, G ^a   Paramasivan, C N ^a,c   Sulochana, S ^a   Mitchison, D A ^b  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

Author keywords

Bactericidal; Gatifloxacin; Moxifloxacin; Mycobacterium tuberculosis; Persistence; Tuberculosis

Indexed keywords

GATIFLOXACIN; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ARTICLE; BACTERIAL COUNT; DRUG ACTIVITY; MEDICAL RESEARCH; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TUBERCULOSIS;

EID: 33845967822     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.6.617     Document Type: Article

References (25)

1. Mitchison DA, Coates ARM. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr Pharm Des 2004; 10: 3285-3295.
2. O'Brien RJ. Development of fluoroquinolones as first-line drugs for tuberculosis - at long last! Am J Respir Crit Care Med. 2003; 168: 1-2.
3. Tuberculosis Research Centre, Indian Council of Medical Research, Chennai. Shortening short course chemotherapy. A randomized clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Ind J Tub 2002; 49: 27-38.
4. World Health Organization. Treatment of TB. Guidelines for national programmes. Third edition. WHO, Geneva. 2002.
5. Nuermberger EL, Yoshimatsu T, Tyagi S et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-426.
6. Mitchison DA. Fluoroquinolones in the treatment of tuberculosis: a study in mice. Am J Respir Crit Care Med 2004; 169: 334-345.
7. Herbert D, Paramasivan CN, Venkatesan P, Kubendiran G, Prabhakar R, Mitchison DA. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on log-arithmic-and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2296-2299.
8. Mitchison DA. The Garrod Lecture. Understanding the chemotherapy of tuberculosis - current problems. J Antimicrob Chemother 1992; 29: 477-493.
9. Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic-and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 627-631.
10. Mitchison DA, Selkon JB. The bactericidal activities of antituberculous drugs. Am Rev Respir Dis 1956; 74S: 109-116.
11. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 1994; 13: 908-914.
12. McDermott W, Tomsett R. Activation of pyrazinamide and nicotinamide in acidic environment in vitro. Am Rev Tuberc 1954; 70: 748-754.
13. Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981; 123: 367-371.
14. Canetti G. The tubercle bacillus in the pulmonary lesions of man. Histobacteriology and its bearing on the therapy of pulmonary tuberculosis. Springer, New York. 1955.
15. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225.
16. Ellard GA. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle 1969; 50: 144-158.
17. Heifets L, Lindholm-Levy P. Pyrazinamide sterilizing activity in vitro against semi-dormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 1992; 145: 1223-1225.
18. Mitchison DA, Allen BW, Carrol L, Dickinson JM, Aber VR. A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol 1971; 5: 165-175.
19. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300: 230-235.
20. Zhang Y, Mitchison DA. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21.
21. Jindani A, Doré CJ, Mitchison DA. The bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167: 1348-1354.
22. Brindle R, Odhiambo J, Mitchison DA. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilizing activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001; 1: 2.
23. Dickinson JM, Aber VR, Mitchison DA. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am Rev Respir Dis 1977; 116: 627-635.
24. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 796-806.
25. Dickinson J, Guy A, Mitchison DA. Bioavailability of rifampicin in experimental murine tuberculosis. Antimicrob Agents Chemother 1992; 36: 2066-2067.